Unknown

Dataset Information

0

Tumor-Naive Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.


ABSTRACT:

Purpose

Circulating tumor DNA (ctDNA) enables personalized treatment strategies in oncology by providing a noninvasive source of clinical biomarkers. In patients with low ctDNA abundance, tumor-naïve methods are needed to facilitate clinical implementation. Here, using locoregionally confined head and neck squamous cell carcinoma (HNSCC) as an example, we demonstrate tumor-naïve detection of ctDNA by simultaneous profiling of mutations and methylation.

Experimental design

We conducted CAncer Personalized Profiling by deep Sequencing (CAPP-seq) and cell-free Methylated DNA ImmunoPrecipitation and high-throughput sequencing (cfMeDIP-seq) for detection of ctDNA-derived somatic mutations and aberrant methylation, respectively. We analyzed 77 plasma samples from 30 patients with stage I-IVA human papillomavirus-negative HNSCC as well as plasma samples from 20 risk-matched healthy controls. In addition, we analyzed leukocytes from patients and controls.

Results

CAPP-seq identified mutations in 20 of 30 patients at frequencies similar to that of The Tumor Genome Atlas (TCGA). Differential methylation analysis of cfMeDIP-seq profiles identified 941 ctDNA-derived hypermethylated regions enriched for CpG islands and HNSCC-specific methylation patterns. Both methods demonstrated an association between ctDNA abundance and shorter fragment lengths. In addition, mutation- and methylation-based ctDNA abundance was highly correlated (r > 0.85). Patients with detectable pretreatment ctDNA by both methods demonstrated significantly worse overall survival (HR = 7.5; P = 0.025) independent of clinical stage, with lack of ctDNA clearance post-treatment strongly correlating with recurrence. We further leveraged cfMeDIP-seq profiles to validate a prognostic signature identified from TCGA samples.

Conclusions

Tumor-naïve detection of ctDNA by multimodal profiling may facilitate biomarker discovery and clinical use in low ctDNA abundance applications.

SUBMITTER: Burgener JM 

PROVIDER: S-EPMC9401560 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.

Burgener Justin M JM   Zou Jinfeng J   Zhao Zhen Z   Zheng Yangqiao Y   Shen Shu Yi SY   Huang Shao Hui SH   Keshavarzi Sareh S   Xu Wei W   Liu Fei-Fei FF   Liu Geoffrey G   Waldron John N JN   Weinreb Ilan I   Spreafico Anna A   Siu Lillian L LL   de Almeida John R JR   Goldstein David P DP   Hoffman Michael M MM   De Carvalho Daniel D DD   Bratman Scott V SV  

Clinical cancer research : an official journal of the American Association for Cancer Research 20210622 15


<h4>Purpose</h4>Circulating tumor DNA (ctDNA) enables personalized treatment strategies in oncology by providing a noninvasive source of clinical biomarkers. In patients with low ctDNA abundance, tumor-naïve methods are needed to facilitate clinical implementation. Here, using locoregionally confined head and neck squamous cell carcinoma (HNSCC) as an example, we demonstrate tumor-naïve detection of ctDNA by simultaneous profiling of mutations and methylation.<h4>Experimental design</h4>We condu  ...[more]

Similar Datasets

| S-EPMC9636504 | biostudies-literature
| S-EPMC9167274 | biostudies-literature
| S-EPMC12627382 | biostudies-literature
| S-EPMC5063170 | biostudies-literature
2022-03-01 | PXD001438 | Pride